Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.

Jianming XuJie LiChunmei BaiNong XuZhiwei ZhouZhiping LiCaicun ZhouRu JiaMing LuYuejuan ChengChenyu MaoWei WangKe ChengChunxia SuYe HuaChuan QiJing LiKe LiQiaoling SunYongxin RenWeiguo Su

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Surufatinib showed encouraging antitumor activity and manageable toxicities in patients with advanced NETs. Two ongoing phase III studies, validating the efficacy of surufatinib in patients with NETs, will contribute to the clinical evidence.

Keyphrases

phase iii
open label
neuroendocrine tumors
phase ii
double blind
clinical trial
phase ii study
study protocol
placebo controlled
cross sectional
radiation therapy